Doc Akers-White Faces Secret Federal Ruling: What Happened?
Published Date: 12/4/2025
Notice
Summary
Dr. Latania Akers-White from Virginia lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration as of June 30, 2025. This means she can’t prescribe or manage controlled drugs anymore, affecting her medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Akers-White
The DEA revoked Latania Akers-White, M.D.'s Certificate of Registration No. FA2343630 and denied any pending applications to renew, modify, or add registrations in Virginia. The registration revocation order is effective January 5, 2026; her DEA registration had expired on June 30, 2025 and her Virginia medical license was suspended on or about July 11, 2024.
DEA Authority When State License Suspended
Under 21 U.S.C. 824(a)(3) and related provisions, the DEA may suspend or revoke a practitioner's registration when the practitioner's State license or registration has been suspended or revoked so that the practitioner is no longer authorized to handle controlled substances in that State. The agency states that a practitioner must have state authority to dispense controlled substances in the State where they practice to be eligible to maintain a DEA registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17594, Atlantic Treatment Center, LLC; Decision and Order
2026-17592, Thomas Earley, D.D.S.; Decision and Order
2026-17589, Leila Kump, M.D.; Decision and Order
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
Previous / Next Documents
Previous: 2025-21884, Agency Information Collection Activities; Submission of Proposed Information Collection; Online Training Request Form for OMB Review
The Access Board is asking for approval to start a new online form that lets people and local governments easily request training. This change makes it simpler to get help and doesn’t cost anyone extra. You can share your thoughts on this plan until January 5, 2026.
Next: 2025-21886, Endangered and Threatened Species; Issuance of Enhancement of Survival and Incidental Take Permits for Safe Harbor Agreements, Candidate Conservation Agreements, Conservation Plans, and Recovery Activities; January 1, 2024, Through December 31, 2024
The U.S. Fish and Wildlife Service is sharing a list of permits issued in 2024 that allow certain activities affecting endangered and threatened species. These permits help people and groups safely work on conservation projects, recovery efforts, and habitat plans without breaking the law. This update keeps everyone informed about who’s involved, what’s allowed, and when these permits apply throughout the year.